Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Build A Bear Workshop Inc (BBW) vs Novavax Inc (NVAX) Price & Performance

Build A Bear Workshop IncTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Build A Bear Workshop Inc vs Novavax Inc — how do they compare? Build A Bear Workshop Inc trades at $36.88 (market cap $467.15M), while Novavax Inc trades at $7.95 (market cap $1.30B). The key difference: Novavax Inc is far larger — about 2.8× Build A Bear Workshop Inc's market cap, and Build A Bear Workshop Inc pays a 2.47% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.

BBWNVAX
Market Cap
$467.15M$1.30B
Sector
Consumer CyclicalHealth
52-Week High
$75.85$11.19
52-Week Low
$29.84$6.22
Enterprise Value
$566.59M$879.40M
Dividend Yield
2.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Build A Bear Workshop Inc

Build-A-Bear Workshop (BBW) trades at $36.86, up 6.19% today, with a bullish technical signal and strong analyst support. The stock exhibits attractive valuation metrics, including a P/E of 8.73 and P/S of 0.92, alongside robust profitability with a 10.48% net income margin and 35.87% ROE. Recent earnings have consistently beaten estimates, and the company maintains a debt-free balance sheet while executing a growth strategy focused on international expansion and brand partnerships.

The outlook for BBW is positive, driven by earnings momentum and a consensus price target of $62.50 implying significant upside. Key risks include near-term consumer spending volatility and execution of expansion plans, but strong fundamentals and shareholder returns via dividends support a favorable risk-reward profile for long-term investors.

Novavax Inc

Novavax (NVAX) trades at $7.95, up 2.71% with a bullish technical signal despite negative profitability metrics. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 but negative net income margins. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook while cutting expenses. Analyst sentiment remains positive with 74% buy ratings.

Investment outlook balances strong partnerships and pipeline potential against persistent cash burn and negative equity. The Sanofi collaboration and Matrix-M adjuvant platform offer growth catalysts, but operational losses and high debt levels present significant risks. Stock appears undervalued on some metrics but requires careful monitoring of cash flow sustainability.

Returns comparison

Trailing returns across standard periods

About Build A Bear Workshop Inc

Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.

Read more on BBW

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX